JPMorgan analyst Tessa Romero raised the firm’s price target on Edgewise Therapeutics (EWTX) to $34 from $33 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics Appoints New Chief Financial Officer
- Edgewise Therapeutics CFO Michael Carruthers to retire, Michael Nofi to succeed
- Edgewise Therapeutics Reports Q3 2025 Financial Results
- Edgewise Therapeutics reports Q3 EPS (39c), consensus (40c)
- Edgewise Therapeutics price target raised to $33 from $30 at JPMorgan